<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04346472</url>
  </required_header>
  <id_info>
    <org_study_id>UF9647</org_study_id>
    <nct_id>NCT04346472</nct_id>
  </id_info>
  <brief_title>Longitudinal MRI Assessment in Patients With Diffuse Low-grade Gliomas</brief_title>
  <acronym>SPECIFY</acronym>
  <official_title>Retrospective Longitudinal Follow-up in Patients With Diffuse Low-grade Glioma With Multimodal MRI Assessment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective longitudinal follow-up in patients with diffuse low-grade glioma with
      multimodal MRI assessment
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2016</start_date>
  <completion_date type="Actual">January 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Longitudinal variation of the relative regional cerebral blood volume</measure>
    <time_frame>1 day</time_frame>
    <description>Longitudinal variation of the relative regional cerebral blood volume from first pass perfusion imaging data for each MRI performed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collection of histological</measure>
    <time_frame>1 day</time_frame>
    <description>Collection of histological</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collection of radiological</measure>
    <time_frame>1 day</time_frame>
    <description>Collection of radiological</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collection of clinical varaibles</measure>
    <time_frame>1 day</time_frame>
    <description>Collection of clinical varaibles</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">200</enrollment>
  <condition>Low-grade Glioma</condition>
  <arm_group>
    <arm_group_label>Gliomes de grade II initial</arm_group_label>
    <description>Gliomes de grade II initial</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Repeated Measurements of the relative regional cerebral blood volume</intervention_name>
    <description>Repeated Measurements of the relative regional cerebral blood volume variation through an every 6 monts Magnetic Resonance Imaging use.</description>
    <arm_group_label>Gliomes de grade II initial</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with diffuse low-grade glioma (WHO grade II)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Initial WHO grade II

          -  At least 3 exploitable MRI each including a morphologic FLAIR sequence and perfusion
             imaging

        Exclusion criteria:

        -Major protected person ( trusteeship, curatorship, justice safeguard)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas MENJOT DE CHAMPFLEUR, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioma</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Magnetic Resonance Angiography</keyword>
  <keyword>Disease Progression</keyword>
  <keyword>Supratentorial Neoplasms</keyword>
  <keyword>Blood Volume</keyword>
  <keyword>Contrast Media</keyword>
  <keyword>Gadolinium DTPA</keyword>
  <keyword>Image Processing, Computer-Assisted</keyword>
  <keyword>Neovascularization, Pathologic</keyword>
  <keyword>Diffuse low grade glioma</keyword>
  <keyword>Relative regional cerebral blood volume ( rRCBV)</keyword>
  <keyword>Early prognosis of anaplasic transformation</keyword>
  <keyword>Diffuse low grade glioma anaplasic transformation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

